Semaglutide vs Tirzepatide: Which GLP-1 is Right for You?

One paragraph verdict: tirzepatide produces more weight loss per unit of GI side effect, and SURMOUNT-1's 20.9% average loss makes it the most effective approved agent. Semaglutide counters with the longest track record in the class — including the cardiovascular outcomes data from the STEP program that regulators and clinicians weight heavily — and remains the backbone of the entire incretin category. If maximum weight loss with a known safety profile is the goal, tirzepatide wins on the averages. If long-term cardiovascular safety matters most to you, or tirzepatide is unavailable in your region, semaglutide is the most data-rich choice in existence.

Semaglutide is a GLP-1 receptor agonist — a synthetic version of the GLP-1 hormone that signals fullness to the brain, slows stomach emptying, and improves insulin sensitivity. Its ~7-day half-life is what makes once-weekly dosing possible. As Wegovy it is FDA-approved for chronic weight management; as Ozempic it treats type 2 diabetes. The STEP trial program is the largest body of weight-loss evidence in the class: STEP 1 reported 14.9% average body weight loss at 68 weeks, with a cardiovascular outcomes trial (SELECT) showing reduced major adverse cardiac events in people with established cardiovascular disease. Full details: the semaglutide guide.

Tirzepatide activates two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The GIP component adds a second incretin pathway — and the leading theory is that it also softens the GLP-1 GI side-effect burden, which is why tirzepatide tends to be tolerated better per pound lost. As Zepbound it is approved for chronic weight management; as Mounjaro it treats type 2 diabetes. SURMOUNT-1 reported 20.9% average body weight loss at 72 weeks — the highest figure ever recorded for an approved agent. Full details: the tirzepatide guide.

GLP-1 and GIP are both incretin hormones released in the gut after eating. Semaglutide maxes out one pathway; tirzepatide recruits both. In head-to-head metabolic terms the dual agonism shows up as greater appetite suppression, better glycemic control, and — critically — weight loss that keeps going longer before plateauing. The trade: the dual mechanism gives tirzepatide a shorter clinical track record (SURMOUNT-1 ran 72 weeks; semaglutide's outcome data now stretches years). Mechanism novelty is the axis the whole comparison turns on: more pathways recruited vs more history known.

Caveats that matter: STEP and SURMOUNT were separate trials with different populations and durations, so the 15% vs 21% comparison is an across-trial estimate, not a single head-to-head result — SURPASS-2 (a true head-to-head, in type 2 diabetes, against the 1 mg semaglutide dose) is the cleanest direct evidence and it also favored tirzepatide on weight. Second: trial averages hide huge individual spread — non-responders exist at meaningful rates for both compounds, and a meaningful minority of tirzepatide users lose 25%+ while some semaglutide users lose under 5%. Third: both compounds plateau. The difference is that tirzepatide keeps descending for more weeks before the plateau arrives.

• •Semaglutide: 0.25 mg weekly for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg — stepping roughly every 4 weeks as tolerated, over 4–8 months to the full maintenance dose. Research protocols cycle 16–20 weeks with 4–8 week breaks.
• •Tirzepatide: 2.5 mg weekly, +2.5 mg every 4 weeks up to 15 mg. Many protocols deliberately cap at 7.5–10 mg, where most of the benefit concentrates, and reserve 12.5–15 mg for plateaus. Research protocols cycle 16–24 weeks with breaks.
• •Both are subcutaneous injections, once weekly, same-day dosing.
• •Never combine them in the same week — they share the GLP-1 receptor pathway, and stacking two incretin agonists multiplies GI toxicity for zero added benefit. They are alternatives, not partners.

The week-by-week titration mechanics for both compounds are drawn out in detail — including plateau handling and break scheduling — in the GLP-1 dosing timeline guide.

The profile shape is identical — incretin side effects are schedule-dependent more than drug-dependent. Slow titration is the single biggest lever on tolerability for both. The shared hard exclusions: personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, gastroparesis, pregnancy, and breastfeeding. Rapid weight loss with either compound also raises gallstone risk — yet another reason the titration schedule matters.

Brand-name list prices for Wegovy and Zepbound sit in the same high tier (roughly $1,000+/month uninsured in the US) — cost rarely decides between them; coverage does. Insurance and national health systems differ regionally on which of the two is covered for which indication, and coverage shifts month to month. Outside the regulated pharmacy channel, both compounds circulate as research chemicals of wildly variable purity — the quality risk there is far higher than the price difference. Availability overall: semaglutide has been on the market longer and is more widely distributed globally, including an oral formulation (Rybelsus); tirzepatide supply has improved from the early shortages but availability still trails semaglutide in some markets.

• •Choose semaglutide if: you want the compound with the longest human track record and cardiovascular outcomes data, it is the covered option for you, your target loss is under ~15% of body weight, or you are starting your first incretin protocol with the most predictable history.
• •Choose tirzepatide if: your target is 15%+ of body weight, you want the best tolerability-per-result, or you plateaued on semaglutide — switching GLP-1s after a true plateau is a legitimate next step rather than a failure.
• •Choose neither (yet) if: you have any of the class contraindications — MTC/MEN2 history, pancreatitis, gastroparesis, pregnancy — or no plan for protein intake and resistance training. At these rates of loss, muscle preservation is determined by habits, not by which receptor agonist you choose.
• •Either way: titrate slowly, run 16–24 week cycles with planned breaks, and let the protocol builder screen your conditions and medications before you commit.